[Erbium 169 synoviortheses and infiltrations of triamcinolone hexacetonide in metatarsophalangeal arthritis of chronic inflammatory rheumatism].
The authors report their experience in the treatment of metatarsophalangeal arthritis of chronic inflammatory rheumatism by Erbium 169 synoviortheses (112 joints treated) and by infiltrations of triamcinolone hexacetonide (53 joints treated). The steroid appears to have a marked early superiority as it gives 85% good results compared to 61.6% for Erbium 169 after a period of one to three months. However, its results then deteriorate more rapidly and after 6 months, the proportion of good results is greater with the radioactive treatment (64% compared to 46.7%). The authors consider it reasonable to use triamcinolone hexacetonide as the first line treatment as it is easier to manage and less expensive, reserving the radioactive synoviortheses for later with the prospect of more lasting results.
D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D004871:Erbium / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007270:Injections, Intra-Articular; D008297:Male; D008683:Metatarsophalangeal Joint / Q000187:drug effects / Q000528:radiation effects; D008875:Middle Aged; D011868:Radioisotopes / Q000627:therapeutic use*; D012216:Rheumatic Diseases / Q000628:therapy; D013997:Time Factors; D014033:Toe Joint / Q000187:drug effects / Q000528:radiation effects; D014222:Triamcinolone Acetonide / Q000031:analogs & derivatives* / Q000627:therapeutic use
D011868:Radioisotopes; D004871:Erbium; D014222:Triamcinolone Acetonide; C005900:triamcinolone hexacetonide
Synoviorthèses à l'erbium 169 et infiltrations d'hexacétonide de triamcinolone dans les arthrites métatarsophalangiennes des rhumatismes inflammatoires chroniques.